Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

INTRODUCTION. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vincenzi, Bruno, Santini, Daniele, Russo, Antonio, Addeo, Raffaele, Giuliani, Francesco, Montella, Liliana, Rizzo, Sergio, Venditti, Olga, Frezza, Anna Maria, Caraglia, Michele, Colucci, Giuseppe, Del Prete, Salvatore, Tonini, Giuseppe
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2010
Témata:
Hepatobiliary
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227883/
https://ncbi.nlm.nih.gov/pubmed/20051477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0143
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky